Silencing SOX2OT reduces viability and migration in lung cancer cells via lncRNA and protein regulation
Medical Oncology · 2025
DOI: 10.1007/s12032-025-03085-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2025. Verfasst von Mohadeseh Zarei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Ir…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Cell Movement, Lung Neoplasms. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Center for international Scientific studies & Collaborations (CISSC), Ministry of science Research and Technology of Iran, National Institute of Genetic Engineering and Biotechnology of Iran.
Abstract (Originalsprache)
Long non-coding RNAs (lncRNAs) play crucial role in tumor development and are being explored as potential therapeutic targets in lung cancer. Both SOX2OT and SOX2 are consistently overexpressed in lung cancer, suggesting that SOX2OT may play a significant role in its development. This study examines how knocking down SOX2OT affects the expression of specific lncRNAs (LINC00982, LINC00668, SNHG7), the gene P16, and key cell cycle-regulating proteins (HSP90AA1, EP300, YES1) in lung cancer cells. Silencing of SOX2OT in A549 and Calu-3 cells led to a marked reduction in its expression. This downregulation was accompanied by decreased levels of SNHG7 and LINC00668, while LINC00982 and P16 transcripts were strongly induced. At the protein level, EP300, HSP90AA1, and YES1 were substantially reduced, whereas P16 was notably elevated. Functionally, suppression of SOX2OT impaired cell viability and significantly limited migratory capacity. In parallel, apoptosis assays demonstrated a pronounced increase in apoptotic cell populations following SOX2OT knockdown. SOX2OT regulates specific lncRNAs and proteins involved in lung cancer survival and migration. Silencing SOX2OT significantly reduces viability, migration, and survival of lung cancer cells, suggesting its potential as a therapeutic target. Further in vivo validation and rescue experiments are needed to confirm these mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
- Department of Medical Physics, M. Smoluchowski Institute of Physics, Jagiellonian University, ul. S. Łojasiewicza 11, 30-348, Krakow, Poland.
- Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Jam@nigeb.ac.ir.
Förderung
- Center for international Scientific studies & Collaborations (CISSC), Ministry of science Research and Technology of Iran
- National Institute of Genetic Engineering and Biotechnology of Iran
Zitieren
APA
Zarei, M., Dinari, A., Jahangiri, B., Asadollahi, E., & Raheb, J. (2025). Silencing SOX2OT reduces viability and migration in lung cancer cells via lncRNA and protein regulation. Medical Oncology. https://doi.org/10.1007/s12032-025-03085-6
Vancouver
Zarei M, Dinari A, Jahangiri B, Asadollahi E, Raheb J. Silencing SOX2OT reduces viability and migration in lung cancer cells via lncRNA and protein regulation. Medical Oncology. 2025. doi:10.1007/s12032-025-03085-6
BibTeX
@article{Zarei2025,
author = {Zarei, Mohadeseh and Dinari, Ali and Jahangiri, Babak and Asadollahi, Elahe and Raheb, Jamshid},
title = {Silencing SOX2OT reduces viability and migration in lung cancer cells via lncRNA and protein regulation},
journal = {Medical Oncology},
year = {2025},
doi = {10.1007/s12032-025-03085-6}
}
EUVIMED